Bipolar II disorder (BDII) is one of the mental, neurological and substance-use disorders that constitute the global burden of disease. It is a neurodevelopmental psychiatric disorder , but little is known about its biological mechanism. There was no case with comorbid substance use disorder that could have confounded diagnosis. Once being diagnosed with BDII, all the patients were continuously treated with one or two mood stabilizers, and with antipsychotics if necessary. Thus having more episodes was not due to incorrect treatment. The findings
suggest that BDII is heterogeneous and that there may be a subgroup of patients with BDII who do not have hypomanic episodes in early stage but respond poorly to mood stabilizers. The ages of the 14 patients (4 men and 10 women) included in further investigation were between 43 and 77. Two of them had comorbid anxiety disorder. Based on the time from the first visit to be diagnosed with bipolar II disorder, patients were clearly divided into 2 groups, one with a diagnosis of less than 2 years (the 脙垄芒聜卢脜聯shorter group脙垄芒聜卢脗聺) that included 8 patients, and the other with a diagnosis of more than 5 years (the 脙垄芒聜卢脜聯longer group脙垄芒聜卢脗聺) that included 6
patients.
Yasuko Fuse-Nagase, Time to Diagnosis Possibly Reflects Bipolar II Disorder Heterogeneity
Last date updated on June, 2025